Latest news with #CureVac
Yahoo
26-05-2025
- Business
- Yahoo
CureVac First Quarter 2025 Earnings: Misses Expectations
Revenue: €893.0k (down 93% from 1Q 2024). Net loss: €52.1m (loss narrowed by 26% from 1Q 2024). €0.23 loss per share (improved from €0.31 loss in 1Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 73%. Earnings per share (EPS) also missed analyst estimates by 26%. Looking ahead, revenue is expected to decline by 34% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 17%. Performance of the American Biotechs industry. The company's shares are up 5.7% from a week ago. We should say that we've discovered 2 warning signs for CureVac that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
26-05-2025
- Business
- Forbes
Will Moderna's Rally Continue?
CHONGQING, CHINA - APRIL 26: In this photo illustration, the logo of Moderna, Inc. is displayed on a ... More smartphone screen, with the company's branding visible in the background, on April 26, 2025, in Chongqing, China. (Photo illustration by) Moderna (NASDAQ: MRNA) has caught the market off guard with a significant recovery in recent days – reaching current levels of approximately $27 after hitting a five-year low of $23.15 last week – following the FDA's decision to continue advising annual COVID-19 vaccinations for high-risk populations. However, this abrupt rally appears to be a singular occurrence – competitors such as Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), and CureVac (NASDAQ:CVAC) did not replicate Moderna's increase – implying the rise was primarily fueled by the FDA guidance rather than a wider sector uptrend. Nevertheless, the overarching context tempers any lasting excitement. Moderna's stock still remains significantly below its 52-week peak of $170.47 and has decreased by over 65% in the last year. Year-to-date, the stock has declined nearly 40%, reflecting investor worries regarding decreasing vaccine revenues, escalating operating losses, and the absence of near-term growth catalysts. With diminished vaccine demand and increasing competition in the mRNA sector, the recent upsurge may not signify a sustainable turnaround, but instead, a fleeting reaction to favorable regulatory news. As part of this in-depth analysis, we investigate whether one should Buy or Fear Moderna stock. Despite the recent short-term gains, Moderna continues to face significant fundamental challenges. Revenues have dropped by 38.2% year-over-year, falling from $6.8 billion to $3.2 billion in the most recent twelve-month period. The downturn is even more severe on a quarterly basis, with a 35.9% year-over-year decline. This represents the third consecutive year of revenue recession, with the average top-line decrease now at 45.5% annually over the past three years. The company's profitability indicators offer limited solace. Moderna reported a net loss of $3.4 billion during the last four quarters, accompanied by an alarming net income margin of -106.9%. Its operating income margin and cash flow margin are equally bleak at -118.8% and -97.2%, respectively. In summary, the company continues to deplete cash reserves with few indicators of operational recovery. At first sight, Moderna's valuation multiple, indicated by a P/S ratio of 3.2 times, seems neutral when compared to the broader market, aligning its valuation multiple with that of the general market. However, these metrics may conceal deeper risks. Revenue clarity is diminishing, pipeline commercialization is still years away, and cash burn remains elevated – factors that introduce substantial downside risks not captured by a simple P/S evaluation. Moderna's stock has also displayed increased sensitivity during market declines. In the 2022 inflation surge, the stock nosedived 53.4%, compared to a 25.4% drop in the S&P 500. During the COVID-19 pandemic and even the 2008 financial crisis, it lagged behind both the market and many of its biotech counterparts. This history of poor performance during downturns further erodes investor confidence in the stock's capacity to withstand macroeconomic fluctuations. A comparison with Moderna's competitors highlights its current vulnerabilities. While companies like Pfizer and Seagen face their own difficulties, they maintain more stable revenue streams and a broader range of products. Sarepta Therapeutics and Alnylam Pharmaceuticals have made strides in rare disease pipelines with relatively steady financial performance. Moderna's peers have generally not endured such steep financial declines, nor have they drastically adjusted their guidance in recent months. The absence of a similar rally among these companies in the past several days indicates that Moderna's rise was not part of a sector-wide re-evaluation but rather a temporary reaction to regulatory developments. Moderna's recent stock surge is, at most, a fleeting respite in a longer narrative of declining revenues, escalating losses, and a challenging route to profitability. Its solid balance sheet and cash reserves provide some cushion, but without tangible advancements in pipeline commercialization or a shift in vaccine sales trends, the stock remains fundamentally at risk. The current valuation may appear reasonable, but it fails to fully account for the risks associated with dwindling revenues and delayed growth. Although the FDA's updated guidance lifted sentiment, the sustainability of this rally will necessitate more than regulatory optimism. Investors should monitor closely for concrete improvements in revenue patterns and updates on Moderna's pipeline development before considering this rebound as anything more than a short-term occurrence. Investing in a single stock like Moderna can be perilous. Conversely, the Trefis High Quality (HQ) Portfolio, consisting of 30 stocks, has a history of comfortably outperforming the S&P 500 over the last four years. Why is that? Collectively, HQ Portfolio stocks delivered superior returns with less risk compared to the benchmark index, providing a steadier investment experience as demonstrated in HQ Portfolio performance metrics.
Yahoo
24-05-2025
- Business
- Yahoo
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M
Over the last 7 days, the United States market has dropped 1.1%, but it is up 9.1% over the past year, with earnings forecast to grow by 14% annually. For those looking to invest in smaller or newer companies, penny stocks — despite their somewhat outdated name — can still offer surprising value when paired with solid financial foundations. This article highlights three such penny stocks that present compelling opportunities due to their financial strength and potential for growth. Name Share Price Market Cap Financial Health Rating SideChannel (OTCPK:SDCH) $0.052 $11.47M ★★★★★★ Perfect (NYSE:PERF) $1.79 $184.35M ★★★★★★ WM Technology (NasdaqGS:MAPS) $1.05 $188.36M ★★★★★★ CureVac (NasdaqGM:CVAC) $3.19 $963.67M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $4.35 $56.66M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.54 $87.41M ★★★★★★ Table Trac (OTCPK:TBTC) $4.70 $22.12M ★★★★★★ BAB (OTCPK:BABB) $0.812625 $5.88M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.16 $72.4M ★★★★★☆ New Horizon Aircraft (NasdaqCM:HOVR) $0.9001 $28.87M ★★★★★★ Click here to see the full list of 735 stocks from our US Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases, with a market cap of approximately $253.73 million. Operations: Allogene Therapeutics, Inc. has not reported any revenue segments. Market Cap: $253.73M Allogene Therapeutics, Inc., a pre-revenue clinical-stage company with a market cap of approximately US$253.73 million, is focused on developing allogeneic T cell therapies for cancer and autoimmune diseases. Despite being unprofitable and experiencing significant insider selling recently, the company's short-term assets exceed both its short- and long-term liabilities, providing some financial stability. Recent developments include FDA Fast Track Designations for ALLO-329 in treating autoimmune diseases and promising data from trials like TRAVERSE for ALLO-316 in renal cell carcinoma. However, the stock remains highly volatile with no profitability forecasted in the near term. Take a closer look at Allogene Therapeutics' potential here in our financial health report. Understand Allogene Therapeutics' earnings outlook by examining our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States, with a market cap of approximately $118.03 million. Operations: Neumora Therapeutics, Inc. currently does not report any revenue segments. Market Cap: $118.03M Neumora Therapeutics, Inc., with a market cap of US$118.03 million, is a pre-revenue clinical-stage biopharmaceutical company. The firm is currently facing challenges as it received a notice from Nasdaq for non-compliance with the US$1 minimum bid price requirement, risking potential delisting unless resolved by November 2025. Despite being debt-free and having short-term assets of US$254.9 million exceeding liabilities, Neumora remains unprofitable with increasing losses reported at US$67.99 million for Q1 2025. The board has proposed a reverse stock split to maintain its Nasdaq listing status, pending shareholder approval later this month. Get an in-depth perspective on Neumora Therapeutics' performance by reading our balance sheet health report here. Gain insights into Neumora Therapeutics' future direction by reviewing our growth report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Kidoz Inc. operates a mobile advertising platform targeting children, teens, and families across various regions including Europe and North America, with a market cap of $32.83 million. Operations: The company generates revenue primarily through its Ad Tech Advertising sales, totaling $14 million. Market Cap: $32.83M Kidoz Inc., with a market cap of US$32.83 million, operates a mobile advertising platform and has recently transitioned to profitability, reporting net income of US$0.35 million for 2024 compared to a loss the previous year. The company generated US$14 million in revenue primarily from its Ad Tech Advertising sales, marking steady growth from the prior year. Kidoz is debt-free, with short-term assets of US$8 million comfortably covering liabilities of US$3.8 million, and it trades significantly below estimated fair value. While management is relatively new with an average tenure of three years, they are considered experienced in guiding the company's financial health forward. Click here and access our complete financial health analysis report to understand the dynamics of Kidoz. Learn about Kidoz's future growth trajectory here. Get an in-depth perspective on all 735 US Penny Stocks by using our screener here. Curious About Other Options? We've found 17 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:ALLO NasdaqGS:NMRA and OTCPK:KDOZ.F. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial Application filed in Europe with decision expected in Q2 2025 Glioblastoma study fully enrolled with Part B of Phase 1 CVGBM trial completing enrolment in Q1 2025; go/no-go decision on moving to Phase 2 planned for H2 2025 First urinary tract infection vaccine moving forward with U.S. IND filing planned for H2 2025 Core mRNA patents upheld as European Patent Office confirmed validity of two key patents in amended form; infringement hearing against BioNTech/Pfizer before the Regional Court Düsseldorf set for July 1, 2025 Strong cash and cash equivalents position of €438.3 million as of March 31, 2025; reaffirming expected cash runway into 2028 TÜBINGEN, GERMANY and BOSTON, MA / ACCESS Newswire / May 20, 2025 / CureVac N.V. (Nasdaq:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the first quarter of 2025 and provided a business update. "We entered 2025 with a strong momentum and robust balance sheet, driven by progress across our oncology and infectious disease programs, as well as successful execution of our strategic realignment," said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. "With the FDA's clearance of the IND for our lung cancer program and our glioblastoma study fully enrolled, we are steadily advancing an oncology pipeline that addresses high-unmet-need tumors. At the same time, we believe the European Patent Office's recent rulings upholding two of our patents in amended form confirm the strength of our mRNA intellectual property estate. Backed by €438 million in cash, we are well positioned to unlock multiple pipeline catalysts later this year and continue to expand and execute on our next generation mRNA portfolio." Selected Business Updates Oncology CureVac is strengthening its oncology pipeline following two complementary approaches: off-the-shelf precision immunotherapies targeting tumor antigens shared across different patient populations and/or tumor types as well as fully personalized precision immunotherapies based on a patient's individual tumor genomic profile. CVGBM (glioblastoma): Data from Phase 1 Part B and the decision on advancing the program to Phase 2 remain on track for H2 2025. Enrolment was completed in Q1 2025 and data in H2 2025 is expected to include 20 patients with a follow up period of at least 6 months. CVHNLC (squamous non-small cell lung cancer): U.S. Phase 1 initiation anticipated in H2 2025 following receipt of FDA Investigational New Drug (IND) clearance; Clinical Trial Application (CTA) filed in Europe with decision expected Q2 2025. As previously communicated, first Phase 1 study with a personalized precision immunotherapy candidate expected to start in H2 2026. Prophylactic Vaccines Urinary tract infection (UTI) program announced in November 2024 progressing on track. FDA IND submission scheduled for H2 2025 and start of Phase 1 trial planned for H1 2026. Protection of Intellectual Property Rights European Patent Office largely dismisses, subject to amendments, oppositions filed in December 2023 by BioNTech SE, Pfizer Inc., and others challenging the validity of EP 3 708 668 B1 and EP 4 023 755 B1 with the infringement hearing scheduled for July 1, 2025, before the Regional Court Düsseldorf. A positive infringement decision would trigger proceedings to assess damages in the same court. Both patents EP 3 708 668 B1 and EP 4 023 755 B1 describe split poly-A tail technology, which enhances medical efficacy by improving expression of the protein encoded on an mRNA construct, a foundational invention of CureVac. As previously communicated, jury trial in U.S. litigation before the U.S. District Court of the Eastern District of Virginia is planned for September 8, 2025. Financial Update for the First Quarter of 2025 Cash Position Cash and cash equivalents amounted to €438.3 million at the end of March 2025, decreasing from €481.7 million at the end of December 2024. In the first three months of 2025, cash used in operations was mainly allocated to ongoing research and development (R&D) activities to advance candidates in oncology precision immunotherapies and prophylactic vaccines and to further develop CureVac's mRNA technology. As a result of the strategic restructuring initiated in July 2024, the cash outflow for the first quarter of 2025 decreased compared to the first quarter of 2024. CureVac completed the intended workforce reduction as part of the strategic restructuring resulting in decreased personnel expenses, while implementing further cost reductions and increasing cost discipline through the organization. The company reaffirms its expected cash runway into 2028. Revenues Revenues amounted to €0.9 million for the first quarter of 2025, representing a decrease of €11.5 million from €12.4 million for the same period in 2024. The year-on-year decrease was primarily driven by lower revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licence Agreement as well as lower sales to CRISPR Therapeutics. For the three months ending March 31, 2025, total revenues of €0.3 million and €0.6 million were recognized with GSK and CRISPR Therapeutics, respectively, compared to €8.9 million and €3.5 million in the prior year period. Operating Result Operating loss amounted to €54.7 million for the first quarter of 2025, representing a decrease of €18.6 million from €73.3 million for the same period in 2024. The decrease year-over-year is primary attributable to the implemented cost reductions initiated with the strategic restructuring in July 2024: Cost of sales decreased significantly due to the change in strategy associated with the new license agreement with GSK, resulting to a change in the activities of the organization towards R&D. As CureVac's manufacturing organization is now solely serving the R&D pipeline, following the change such costs are no longer recognized as cost of sales. In addition, the prior year period was impacted by extraordinary expenses as part of an arbitration ruling for Contract Manufacturing Organization (CMO) activities related to the first-generation COVID-19 vaccine. R&D expenses increased primarily due to the costs of CureVac's manufacturing organization being recognized as R&D expenses rather than cost of sales. The increase was partially offset by implemented cost reductions initiated with the strategic restructuring in July 2024. General and administrative expenses decreased primarily due to lower personnel expenses following the implemented workforce reduction as part of the strategic restructuring. Financial Result (Finance Income and Expenses) Net financial result for the first quarter of 2025 amounted to €3.0 million, representing a decrease of €0.4 million from €3.4 million for the same period in 2024. Pre-Tax Loss Pre-tax loss was €51.7 million for the first quarter of 2025, compared to €69.9 million in the same period of 2024. About CureVac CureVac (Nasdaq:CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized precision immunotherapy candidates to treat cancer. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at CureVac Media and Investor Relations Contact CureVac, Tübingen, GermanyT: +49 7071 9883-0communications@ Forward-Looking Statements of CureVac This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway expectations, timing of various milestones, the impact of restructuring, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, ability to implement our pipeline strategy, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, ability to implement, maintain and improve effective internal controls, reliance on key personnel, reliance on intellectual property protection and the company's and the company's collaborators' ability to obtain, maintain, defend and enforce such intellectual property, scope of intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes and other important factors discussed under the caption "Risk Factors" in the company's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on April 11, 2025, as such factors may be updated form time to time in its other filings with the SEC. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the company's reports and documents filed with the SEC. You may get these documents by visiting EDGAR on the SEC website at Cash and Condensed Consolidated Profit and Loss Data (in € millions) December 31, 2024 March 31, 2025 Cash and Cash Equivalents 481.7 438.3 Three months ended March 31, (in € millions) 2024 2025 Revenue 12.4 0.9 Cost of Sales, R&D, SG&A, Other Operating Expenses & Other Operating Income -85.7 -55.6 Operating Result -73.3 -54.7 Financial Result 3.4 3.0 Pre-Tax Loss -69.9 -51.7 SOURCE: CureVac View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
20-05-2025
- Business
- Associated Press
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
TÜBINGEN, GERMANY and BOSTON, MA / ACCESS Newswire / May 20, 2025 / CureVac N.V. (Nasdaq:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the first quarter of 2025 and provided a business update. 'We entered 2025 with a strong momentum and robust balance sheet, driven by progress across our oncology and infectious disease programs, as well as successful execution of our strategic realignment,' said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. 'With the FDA's clearance of the IND for our lung cancer program and our glioblastoma study fully enrolled, we are steadily advancing an oncology pipeline that addresses high-unmet-need tumors. At the same time, we believe the European Patent Office's recent rulings upholding two of our patents in amended form confirm the strength of our mRNA intellectual property estate. Backed by €438 million in cash, we are well positioned to unlock multiple pipeline catalysts later this year and continue to expand and execute on our next generation mRNA portfolio.' Selected Business Updates Oncology CureVac is strengthening its oncology pipeline following two complementary approaches: off-the-shelf precision immunotherapies targeting tumor antigens shared across different patient populations and/or tumor types as well as fully personalized precision immunotherapies based on a patient's individual tumor genomic profile. Prophylactic Vaccines Protection of Intellectual Property Rights Financial Update for the First Quarter of 2025 Cash Position Cash and cash equivalents amounted to €438.3 million at the end of March 2025, decreasing from €481.7 million at the end of December 2024. In the first three months of 2025, cash used in operations was mainly allocated to ongoing research and development (R&D) activities to advance candidates in oncology precision immunotherapies and prophylactic vaccines and to further develop CureVac's mRNA technology. As a result of the strategic restructuring initiated in July 2024, the cash outflow for the first quarter of 2025 decreased compared to the first quarter of 2024. CureVac completed the intended workforce reduction as part of the strategic restructuring resulting in decreased personnel expenses, while implementing further cost reductions and increasing cost discipline through the organization. The company reaffirms its expected cash runway into 2028. Revenues Revenues amounted to €0.9 million for the first quarter of 2025, representing a decrease of €11.5 million from €12.4 million for the same period in 2024. The year-on-year decrease was primarily driven by lower revenues from GSK following the restructuring of the partnership in July 2024 from a Collaboration into a Licence Agreement as well as lower sales to CRISPR Therapeutics. For the three months ending March 31, 2025, total revenues of €0.3 million and €0.6 million were recognized with GSK and CRISPR Therapeutics, respectively, compared to €8.9 million and €3.5 million in the prior year period. Operating Result Operating loss amounted to €54.7 million for the first quarter of 2025, representing a decrease of €18.6 million from €73.3 million for the same period in 2024. The decrease year-over-year is primary attributable to the implemented cost reductions initiated with the strategic restructuring in July 2024: Financial Result (Finance Income and Expenses) Net financial result for the first quarter of 2025 amounted to €3.0 million, representing a decrease of €0.4 million from €3.4 million for the same period in 2024. Pre-Tax Loss Pre-tax loss was €51.7 million for the first quarter of 2025, compared to €69.9 million in the same period of 2024. About CureVac CureVac (Nasdaq:CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized precision immunotherapy candidates to treat cancer. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at CureVac Media and Investor Relations Contact CureVac, Tübingen, Germany T: +49 7071 9883-0 [email protected] Forward-Looking Statements of CureVac This press release contains statements that constitute 'forward looking statements' as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the 'company') regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, cash runway expectations, timing of various milestones, the impact of restructuring, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as 'anticipate,' 'intend,' 'believe,' 'estimate,' 'plan,' 'seek,' 'project,' 'expect,' 'may,' 'will,' 'would,' 'could,' 'potential,' 'intend,' or 'should,' the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, ability to implement our pipeline strategy, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, ability to implement, maintain and improve effective internal controls, reliance on key personnel, reliance on intellectual property protection and the company's and the company's collaborators' ability to obtain, maintain, defend and enforce such intellectual property, scope of intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes and other important factors discussed under the caption 'Risk Factors' in the company's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 11, 2025, as such factors may be updated form time to time in its other filings with the SEC. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. For further information, please reference the company's reports and documents filed with the SEC. You may get these documents by visiting EDGAR on the SEC website at Cash and Condensed Consolidated Profit and Loss Data SOURCE: CureVac press release
